Found vs MEDVi: Which GLP-1 Provider Is Better?
Short answer: Found scores higher on our rubric, 7.3/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.
Found beats MEDVi overall, scoring 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Found is published $129/mo; total not verified; MEDVi is $179 first month, then $299/mo. Choose Found for insured patients who want their glp-1 coverage checked and their copay minimized. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.
A side-by-side look at Found and MEDVi to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Found
#31 of 54Science-backed weight management platform combining GLP-1 medications with behavioral health coaching and support.
Visit FoundMEDVi
#46 of 54MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDVi| Feature | Found | MEDVi |
|---|---|---|
| Why each one | One of the only GLP-1 platforms that actively coordinates with insurance companies, offers a GLP-1 coverage check, and prescribes from 10+ medications. | Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication. |
| Our Score | 7.3/10 | 5.7/10 |
| Headline Price | published $129/mo; total not verified | $179 first month, then $299/mo |
| Medication Type | Both | Both |
| Insurance Accepted | Yes | No |
| Best For | Insured patients who want their GLP-1 coverage checked and their copay minimized | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Costs vary by insurance status and medication choice rather than one flat rate; run Found's coverage check first to see your exact copay before paying | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #31 | #46 |
| Get started | Visit Found | Visit MEDVi |
Pros & Cons Compared
Found
Pros
- +Active insurance coordination, Found contacts your insurer and reports which GLP-1s are covered, prior auth requirements, and estimated copay
- +10+ medication options including both compounded and brand-name (Wegovy, Zepbound, Wegovy pill), the widest formulary of any platform
- +Typical insured copay of ~$30/mo for most members, dramatically lower than cash-pay alternatives
- +Most members start treatment within one week of completing the health questionnaire
Cons
- −Costs vary by insurance status and medication choice rather than one flat rate; run Found's coverage check first to see your exact copay before paying
- −The insurance navigation process adds steps compared to simple cash-pay platforms; the payoff is the ~$30 typical copay
- −Compounded medication availability may shift with FDA enforcement changes; the 10+ medication formulary lets your clinician move you to a brand-name option if it does
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
Found edges out MEDVi with a score of 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Found is published $129/mo; total not verified; MEDVi is $179 first month, then $299/mo. Found accepts insurance, which can significantly reduce your out-of-pocket costs.
Read Full Reviews
Related comparisons
More head-to-head comparisons involving Found and MEDVi.
- Found vs Elevate Healthfrom $233/mo
- Found vs SynergyRxfrom $199/mo
- Found vs Care Bare Rxfrom $199/mo
- MEDVi vs Direct Meds GLP-1from $297/mo
- MEDVi vs PeterMDfrom $165/mo
- MEDVi vs Yucca Healthfrom $146/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Found · 7.3/10